Marathon Pharmaceuticals will charge $89,000 annually in the U.S. for a decades-old steroidal drug that was approved for U.S. sale for the first time on Thursday, a price that is as much as 70 times higher than the drug’s price overseas.
from WSJ.com: US Business http://ift.tt/2kC4crr
via IFTTT
No comments:
Post a Comment